This document provides recommendations for best practices regarding central venous access devices (CVADs). It discusses site selection, safety protocols to prevent infection, skin antisepsis techniques, tip placement confirmation, dressing selection and changes, device securement, flushing and locking protocols, assessing and treating occlusion, minimizing blood withdrawal, and references to support the recommendations. The goal is to provide effective vascular access care and improve patient outcomes while reducing complications.
Long term outcomes in patients with h fr-ef treated with cabg vs pciRamachandra Barik
RESULTS A total of 12 113 patients (mean [SD] age, 64.8 (11.0) years for the PCI group and 65.6[9.7] years for the CABG group; 5084 (72.5%) male for the PCI group and 4229 (82.9%) malefor the PCI group) were propensity score matched on 30 baseline characteristics: 2397 patients undergoing PCI and 2397 patients undergoing CABG. The median follow-up was 5.2
years (interquartile range, 5.0-5.3). Patients who received PCI had significantly higher rates of
mortality (hazard ratio [HR], 1.6; 95% CI, 1.3-1.7), death from cardiovascular disease (HR 1.4,95% CI, 1.1-1.6), MACE (HR, 2.0; 95% CI, 1.9-2.2), subsequent revascularization (HR, 3.7; 95%
CI, 3.2-4.3), and hospitalization for MI (HR, 3.2; 95% CI, 2.6-3.8) and heart failure (HR, 1.5;95% CI, 1.3-1.6) compared with matched patients who underwent CABG.
Notes to support the presentation 'Introduction to the Visual Infusion Phlebi...ivteam
Notes to support the VIP score presentation.
The Visual Infusion Phlebitis score is a standardised approach to monitoring peripheral IV catheter sites.
The fact that it encourages site observation means that it also has an impact on other peripheral IV catheter problems such as dislodgement, infiltration and infection.
The innovation of this tool is the recognition of the visual nature of peripheral IV problems and the subsequent benefits of a visual tool to identify these issues early.
As health care workers we have a duty of care to monitor the condition of a patients IV site.
Failure to monitor IV sites is seen as failure in duty of care.
The VIP score is internationally acknowledged as a proven standardised tool for the monitoring of peripheral IV catheter sites.
Long term outcomes in patients with h fr-ef treated with cabg vs pciRamachandra Barik
RESULTS A total of 12 113 patients (mean [SD] age, 64.8 (11.0) years for the PCI group and 65.6[9.7] years for the CABG group; 5084 (72.5%) male for the PCI group and 4229 (82.9%) malefor the PCI group) were propensity score matched on 30 baseline characteristics: 2397 patients undergoing PCI and 2397 patients undergoing CABG. The median follow-up was 5.2
years (interquartile range, 5.0-5.3). Patients who received PCI had significantly higher rates of
mortality (hazard ratio [HR], 1.6; 95% CI, 1.3-1.7), death from cardiovascular disease (HR 1.4,95% CI, 1.1-1.6), MACE (HR, 2.0; 95% CI, 1.9-2.2), subsequent revascularization (HR, 3.7; 95%
CI, 3.2-4.3), and hospitalization for MI (HR, 3.2; 95% CI, 2.6-3.8) and heart failure (HR, 1.5;95% CI, 1.3-1.6) compared with matched patients who underwent CABG.
Notes to support the presentation 'Introduction to the Visual Infusion Phlebi...ivteam
Notes to support the VIP score presentation.
The Visual Infusion Phlebitis score is a standardised approach to monitoring peripheral IV catheter sites.
The fact that it encourages site observation means that it also has an impact on other peripheral IV catheter problems such as dislodgement, infiltration and infection.
The innovation of this tool is the recognition of the visual nature of peripheral IV problems and the subsequent benefits of a visual tool to identify these issues early.
As health care workers we have a duty of care to monitor the condition of a patients IV site.
Failure to monitor IV sites is seen as failure in duty of care.
The VIP score is internationally acknowledged as a proven standardised tool for the monitoring of peripheral IV catheter sites.
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...Fundacion EPIC
Presentación de la ponencia "Cierre Percutáneo de Orejuela Izquierda. Evidencia clínica: dónde estamos?" realizada por Raul Moreno en los Diálogos EPIC_Cierre Percutáneo de la Orejuela Izquierda el 15 de Marzo de 2018 en Madrid (España)
Left atrial appendage closure. Clinical evidence; where we are? by Raul Moreno at Diálogos EPIC_Percutaneous left atrial appendage closure, March 15th 2018 in Madrid (Spain)
Long-Term Durability of Transcatheter Aortic Valve ProsthesesShadab Ahmad
Assessments of valve function in the early randomized trial cohorts and registries have consistently shown preserved valve function up to 5 years after TAVR. However, it is well recognized that structural valve degeneration (SVD) with surgical aortic valve bioprostheses is usually not seen until 5 to 10 years post-procedure, and data in this time frame following TAVR are very sparse
Fundación EPIC _ Left atrial appendage closure. Clinical evidence; where we a...Fundacion EPIC
Presentación de la ponencia "Cierre Percutáneo de Orejuela Izquierda. Evidencia clínica: dónde estamos?" realizada por Raul Moreno en los Diálogos EPIC_Cierre Percutáneo de la Orejuela Izquierda el 15 de Marzo de 2018 en Madrid (España)
Left atrial appendage closure. Clinical evidence; where we are? by Raul Moreno at Diálogos EPIC_Percutaneous left atrial appendage closure, March 15th 2018 in Madrid (Spain)
Long-Term Durability of Transcatheter Aortic Valve ProsthesesShadab Ahmad
Assessments of valve function in the early randomized trial cohorts and registries have consistently shown preserved valve function up to 5 years after TAVR. However, it is well recognized that structural valve degeneration (SVD) with surgical aortic valve bioprostheses is usually not seen until 5 to 10 years post-procedure, and data in this time frame following TAVR are very sparse
This focuses on the Consensus Recommendations on the Prevention and Management of Surgical Site Infections in the Philippine Setting by Saguil, Bermudez, Antonio and Cochon, PJSS 2017.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
1. Current best Practice of
CVAD :
Complication and
Management
Dr. Tarek S Kotb
MBBCH
MRCPCH.UK
2. Vascular Access Devices (VADs)
Vascular Access Devices (VADs) are a
common and important part of clinical
practice for the administration of
parenteral fluids, nutrients, medications
and blood products.
In addition, VADs provide a route to
monitor the hemodynamic status of a
client.
Over the last two decades vascular access
device (VAD) technology has advanced and
new treatment regimens have emerged.
These changes bring with them the desire
to support best practice to provide more
effective vascular access care.
3. The desired clinical
goal is positive client
outcomes as
evidenced by
completion of
therapy, absence of
complications and
client satisfaction
with care delivery.
5. Interpretation of Evidence
Levels of Evidence
Ia) Evidence obtained from meta-analysis or systematic review of randomized controlled
trials.
Ib) Evidence obtained from at least one randomized controlled trial.
IIa) Evidence obtained from at least one well-designed controlled study without
randomization.
IIb) Evidence obtained from at least one other type of well-designed quasi-experimental
study without randomization.
III) Evidence obtained from well-designed non-experimental descriptive studies, such as
comparative studies, correlation studies and case studies.
IV) Evidence obtained from expert committee reports or opinions and/or clinical
experiences of respected authorities.
7. site and device selection
Recommendation 1
To determine the most appropriate type of vascular access device,
we need to consider the following factors:
# Prescribed therapy – Level Ib;
# Duration of therapy – Level Ib;
# Physical assessment – Level IV;
# Client health history – Level IV;
# Support system/resources – Level IV;
# Device availability – Level IV;
# Client preference – Level IV.
8. Safety/Infection Prevention and Control
Recommendation 2
prevent the spread of infection by following routine practices and using additional
precautions.( Level IV)
Routine practices include:
■ Hand hygiene;
■ Assessment of client risk factors;
■ Screening;
■ Hazard or risk reduction
■ Application of personal protective equipment (PPE).
(CDC, 2002; Health Canada, 2003).
Alert: Hand hygiene is the
single most important
infection prevention and
control practice.
9. ▪Assessment of client risk factors;
■ Immunosuppression;
■ Coagulopathies;
■ Signs and symptoms of infection;
■ History of exposure to infectious
disease
■ Client response during site
assessment.
10. Screening
Screen families and visitors to
protect the client from potential
risks and encompasses client
feedback e.g. pain ,chills
(CNO, 2004; Ministry of Health and
Long-Term Care (MOHLTC), 2002).
11. Hazard or Risk Reduction
having the client who is
coughing wear a mask during
CVAD care, proper disposal of
infectious waste
(CNO, 2004i; PHAC, 2002
12. Skin Antisepsis
Recommendation 3 level IV
consider the following factors when performing catheter site care using aseptic
technique:
■ Catheter material (composition) : The antiseptic solution must be compatible with the catheter
material (Hadaway, 2003)
■ Antiseptic solution : Studies have shown that 2% chlorhexidine gluconate solution significantly lowers
catheter-related bloodstream infection rates when compared with 10% povidone-iodine and 70% isopropyl alcohol
(LeBlanc & Cobbett, 2000; Maki, Ringer & Alvarado, 1991; Mimoz, et al., 1996; Rosenthal, 2003; Zitella, 2004).
■ Client tolerance (skin integrity,allergies,pain,sensitivity and skin reaction)
Client tolerance and preference may influence the use of antiseptic solutions
13. Drying Times
Required drying timesolution
30 seconds (Hadawy,2003)Chlorhexidine gluconate 2% with alcohol
2 minutes( Panel consensus,2005)Chlorhexidine gluconate without alcohol
2 minutes (Hadaway,2002)Povidone-iodine
Dries quickly, kills bacteria only when first
applied. No lasting bactericidal effect; can
excessively dry the
skin(Hadaway,2002;Sansivero,1998)
70% isopropyl alcohol
14. Tip Placement
Recommendation 4
Nurses will not use the central venous access device (CVAD) until tip placement has been
confirmed. (Level IV)
Three complications caused directly by
incorrect tip position include:-
■ Central venous perforation
■ Thrombosis
■ CVAD dysfunction.
Professional and regulatory organizations recommend
optimal tip position for all CVAD to be the distal
Superior Vena Cava (SVC) and/or the caval/atrial junction.
(Department of Health (DH), 2001b; INS, 2000; ONS, 2004; Ruesch, 2002; Vesely, 2003.)
15. Dressings
Recommendation 5 level IV
consider the following factors when selecting and changing VAD
dressings.
■ Type of dressing; Most studies support and recommend the use of dressings (Larwood,
2000); however, the type of dressing remains controversial (CDC, 2002).
■ Frequency of dressing changes: Dressing changes using aseptic technique should be
completed every 48 hours for gauze and every seven days for TSM dressings or sooner if
contaminated, non-adherent, damp, loose, or visibly soiled (CDC, 2002; Hadaway, 2003b; O’Grady et
al., 2002; Pearson, 1996a, 1996b; Rosenthal, 2003; Ross & Orr, 1997)
■ Client choice,tolerance and lifestyle. A meta-analysis comparing the risk for
catheter-related blood stream infections (CRBSIs) for groups using transparent
dressings versus groups using gauze dressing was reviewed by the Centers for Disease
Control and Prevention (CDC, 2002). The risk for CRBSIs did not differ between the groups
and thus the choice of dressing was a matter of preference (CDC, 2002).
16. Practice Considerations
TRUE OR FALSE
1- Antimicrobial ointments should be applied to insertions sites.
2- Transparent dressings, should be placed on the skin overstreched
and smoothed from the center out to the edge and molded around
the catheter. The edges of the transparent dressing should be
sealed with tape.
3- Implanted vascular access devices, which are healed and not
accessed, do not require a dressing.
17. Securement
Recommendation 5 level III
Nurses must stabilized the VAD in order to:
■ Promote assessment and monitoring of the vascular access site
■ Facilitate delivery of prescribed therapy
■ Prevent dislodgement ,migration ,and/or catheter damage.
phlebitis; infiltration;
extravasation;
dislodgement;
disconnection; and infection
TAPE
SUTURES
SECUREMENT
DEVICES
18. Patency/Flushing/Locking
Recommendation 7 level IV
maintain catheter patency using flushing and locking techniques.
Flushing prevents the mixing of incompatible medications or solutions and/or cleans the
catheter lumen of blood or fibrin buildup.
Locking prevents blood from backing up into the catheter lumen when the device is not in
use
the majority of literature on maintaining patency recommends the use of correct flushing
and locking techniques (RCN, 2003).
The Four Elements of Flushing and Locking
■ Type of solution;
■ Concentration of solution;
■ Volume of solution; and Frequency of administration
19. FLUSHING
Generally, flushing shall be performed:
■ After blood sampling;
■ When converting from continuous to intermittent therapies;
■ Before and after medication administration;
■ Before and after administration of blood components;
■ Before and after intermittent therapy; and
■ For maintenance of a dormant device
20. TECHNICAL PROBLEMS
CAN INFUSE BUT NOT ASPIRATE
£ Something is not right -- - - -- do not ignore this
£ look for pain or swelling particularly when infusing - - - - catheter
problem pinched ,kinked or cracked
£ Could be ball- valve effect caused by fibrin tail
-- - - Alteplase theraby may help
-- -- consultation VAT
21. TECHNICAL PROBLEM
CAN ASPIRATE BUT NOT INFUSE
£ Reverse ball-valve effect
£ Partial obstruction in catheter or implanted port reservoir££
(precipitate ,fibrin , thrombus or lipid)
£ call vascular access team
- possible need for alteplase theraby
- possible need for line exchange or replacement
22. Recommendation 8
Nurses will know what client factors, device characteristics and
infusate factors can contribute to catheter occlusion in order to
ensure catheter patency for the duration of the therapy.
Level IV
23. Recommendation 8
client factors:
should assess clients for the following factors:
■ Disease processes and/or medications that may alter circulation and/or
coagulation status
■ History of clots such as Deep Vein Thrombosis (DVT) and pulmonary
embolus
■ Prior history of device occlusion(s)
■ Client adherence to catheter care protocols
■ Changes in intrathoracic pressure caused by persistent coughing,
retching or vomiting, excessive crying, heavy lifting and vigorous exercise
that can cause blood reflux into the CVAD
24. Recommendation 8
Device Factors (catheter characteristics)
# Choose the appropriate device
# Choose valve technologies that are designed to minimize blood
reflux
# Minimize blood sampling through CVADs due to the increased risk
of fibrin deposits and thrombus device occlusions
# Monitor clients regularly for altered tip position of CVADs
25. Recommendation 8
Infusate Factors
@ pH less than 5 and greater than 9
@ osmolarity greater than 500 Osmol/L
@ Medications that have the potential to precipitate and cause
occlusion
26. Occlusion
Recommendaton 9
assess and evaluate vascular access devices for occlusion in order
to facilitate treatment and improve client outcomes. (Level IV)
Mechanical obstruction of catheter
Catheter obstruction related to medication or parenteral nutrition
Thrombotic catheter obstruction
27. Algorithm for management of a central
venous catheter obstruction.
Lancet. Author manuscript;
available in PMC 2010 Feb 1.
28. Blood Withdrawal
Recommendation 10
Nurses will minimize accessing the central venous access device
(CVAD) in order to reduce the risk of infection and nosocomial blood
loss.
it is important to minimize the number of entries into the central
venous system in order to prevent complications.
To reduce the total amount of blood loss, nurses can incorporate
blood conservation strategies including:
■ Peripheral sampling whenever possible and/or when the clinical
situation does not preclude the use of peripheral sampling
■ Flushing prior to withdrawing;
29. Practical consideration
ways to prevent catheter damage
*Do not clamp catheter with haemostat
*Do not force flush if resistance is met
*Do not use needles
*Only use 10 ml or larger syringes
*Be aware that pinch off sign can result in catheter damage
30. REFERENCES
1. Centers for Disease Control and Prevention (CDC) (2002). Guidelines for the prevention of intravascular catheter-
related infections. Morbidity and Mortality Weekly Report (MMWR) 51 (No. RR-10), 1-29.
2a. Department of Health (DH) (2001a). Guidelines for preventing infections associated with the insertion and
maintenance of central venous catheters: Introduction. Journal of Hospital Infection 47, S13-S19.
2b. Department of Health (DH) (2001b). Guidelines for preventing infections associated with the insertion and
maintenance of central venous catheters. Journal of Hospital Infection 47, S47-S67.
3a. Evidence-Based Practice in Infection Control (EPIC) (2001a). The EPIC project: Developing national evidence-based
guidelines for preventing hospital-acquired infections. National evidence-based guidelines for preventing hospital-
acquired infections associated with the use of central venous catheters.Technical report part A. Available:
http://www.epic.tvu.ac.uk/epicphase/epic1.html
3b. Evidence-Based Practice in Infection Control (EPIC) (2001b). The EPIC project: Developing national evidence-based
guidelines for preventing hospital-acquired infections. National evidence-based guidelines for preventing hospital-
acquired infections associated with the use of central venous catheters.Technical report part B. Available:
http://www.epic.tvu.ac.uk/epicphase/epic1.html
4. Intravenous Nurses Society (INS) (2000). Infusion nursing: Standards of practice. Journal of Intravenous Nursing,23,
S1-S88.
5. Royal College of Nursing (RCN) (2003). Standards for infusion therapy. London: Author.